

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.337; Rifaximin for preventing episodes of overt hepatic encephalopathy

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Norgine Limited <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Leonard Cheshire Disability • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Addaction • Black Health Agency • British Liver Trust • Chinese Healthy Living Centre • Compass UK • Drugs Action • Hepatitis B Foundation UK • Hepatitis B Positive • Hepatitis C TrustLiver4Life <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Geriatrics Society • British Neuropathological Society • Institute of Neurology • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee • All Wales Therapeutics and Toxicology Centre <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Alliance (neomycin) • Concordia (neomycin) • Intraparm laboratories (lactulose) • Mylan (lactulose) • Novartis (lactulose) • Pheonix Labs (neomycin) • Teva UK (lactulose, neomycin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research Trust • MRC Clinical Trials Unit

<ul style="list-style-type: none"> • NHS Liverpool CCG • NHS South Sefton CCG • Welsh Government 	<ul style="list-style-type: none"> • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).